From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
TNIK-IN-3 is a potent, selective and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK), with an IC50 of 0.026 μM. TNIK-IN-3 could also inhibit Flt4 (IC50=0.030 μM), Flt1 (IC50=0.191 μM) and DRAK1 (IC50=0.411 μM). TNIK-IN-3 can be used for the research of colorectal cancer .
FLT4 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Flt4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Flt4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC50s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively .
Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC50 of 4, 25, 32, 44, and 95 nM.
Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM.
Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].
Vandetanib-d6 is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity .
Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC50 of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC50 of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC50 values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC50 values < 10 nM) under hypoxic condition .
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .
FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively .
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-3/FLT4 Protein, Human (HEK293, His) is 752 a.a., with molecular weight of ~130 kDa.
VEGFR-3/FLT4 proteins are tyrosine protein kinase receptors for VEGFC and VEGFD and are critical in adult lymphangiogenesis and embryonic vascular development. It promotes endothelial cell function, angiogenesis, and forms a positive feedback loop that increases VEGFC production. VEGFR-3/FLT4 Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-3/FLT4 Protein, Mouse (HEK293, hFc) is 751 a.a., with molecular weight of 115-160 kDa.
VEGFR-3/FLT4 proteins are tyrosine protein kinase receptors for VEGFC and VEGFD and are critical in adult lymphangiogenesis and embryonic vascular development. It promotes endothelial cell function, angiogenesis, and forms a positive feedback loop that increases VEGFC production. VEGFR-3/FLT4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-3/FLT4 Protein, Mouse (HEK293, His) is 751 a.a., with molecular weight of 95-105 kDa.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGFR-3/FLT4 Protein, Human (HEK293, His-Avi) is 752 a.a., with molecular weight of 110-130 kDa.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, hFc) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-3/FLT4 Protein, Human (HEK293, hFc) is 752 a.a., with molecular weight of ~160 & 85 & 75 kDa, respectively.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGFR-3/FLT4 Protein, Human (Biotinylated, HEK293, His-Avi) is 752 a.a., with molecular weight of 115-130 kDa.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-CC Protein, Human (196a.a, HEK293, His) is the recombinant human-derived VEGF-CC protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-CC Protein, Human (196a.a, HEK293, His) is 196 a.a., with molecular weight of 25-30 kDa.
VEGF-C Protein, a crucial member of the PDGF/VEGF growth factor family, plays a role in vital cellular signaling pathways. As part of this family, VEGF-C likely shares characteristics with related proteins, promoting cell growth, angiogenesis, and lymphangiogenesis. Membership in the PDGF/VEGF growth factor family underscores its role in vascular and lymphatic development regulation. Studying VEGF-C enhances understanding of its functions, potential therapeutic applications, and impact on tissue development. Further exploration can deepen comprehension of VEGF-C's contribution to physiological and pathological conditions. VEGF-C Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of VEGF-C Protein, Human (HEK293, His-Avi) is 125 a.a., with homodimer molecular weight of ~23-30 kDa.
VEGF-C protein is an important member of the PDGF/VEGF growth factor family and plays a role in important cell signaling pathways. As part of this family, VEGF-C may share features with related proteins that promote cell growth, angiogenesis, and lymphangiogenesis. VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) is 125 a.a., with homodimer molecular weight of ~23-30 kDa.
VEGF-CC protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-CC Protein, Mouse/Rat (HEK293, His) is the recombinant mouse, rat-derived VEGF-CC protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-CC Protein, Mouse/Rat (HEK293, His) is 116 a.a., with molecular weight of 14-23 kDa.
VEGF-CC protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-CC Protein, Mouse/Rat (HEK293, Fc) is the recombinant rat, mouse-derived VEGF-CC protein, expressed by HEK293 , with N-hFc labeled tag. The total length of VEGF-CC Protein, Mouse/Rat (HEK293, Fc) is 116 a.a., with molecular weight of ~44 & 34 kDa, respectively.
VEGF-C Protein, Human (116a.a, HEK293) functions in lymphangiogenesis, where it acts on lymphatic endothelial cells (LECs) primarily via its receptor VEGFR-3 promoting survival, growth and migration.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-CC Protein, Human (125a.a, HEK293, His) is the recombinant human-derived VEGF-CC protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGF-CC Protein, Human (125a.a, HEK293, His) is 125 a.a., with molecular weight of ~22.5 kDa.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-C Protein, Human (116a.a, HEK293, His) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-C Protein, Human (116a.a, HEK293, His) is 116 a.a., with molecular weight of ~19.42 kDa.
Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].
Vandetanib-d6 is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].
Inquiry Online
Your information is safe with us. * Required Fields.
